Western Blot
| Name | Preis | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Mouse Axl - Biotin - 50 µg | Anmelden | Anti-Mouse Axl - Biotin - 50 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human β-Amyloid Precursor Protein (AβNT) (APP) - 0.1 mg | Anmelden | Anti-Human β-Amyloid Precursor Protein (AβNT) (APP) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human β-Amyloid Precursor Protein (CT) (APP) - 0.1 mg | Anmelden | Anti-Human β-Amyloid Precursor Protein (CT) (APP) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Acinus (C--Terminus 1) - 0.1 mg | Anmelden | Anti-Human Acinus (C--Terminus 1) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Acinus (C-Terminus 2) - 0.1 mg | Anmelden | Anti-Human Acinus (C-Terminus 2) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Acinus (Intermediate Domain) - 0.1 mg | Anmelden | Anti-Human Acinus (Intermediate Domain) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Acinus (N-Terminus) - 0.1 mg | Anmelden | Anti-Human Acinus (N-Terminus) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Act1 (CT) - 0.1 mg | Anmelden | Anti-Human Act1 (CT) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Act1 (NT) - 0.1 mg | Anmelden | Anti-Human Act1 (NT) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Amino-terminal Enhancer of Split (CT) (AES) - 0.1 mg | Anmelden | Anti-Human Amino-terminal Enhancer of Split (CT) (AES) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Apoptosis Antagonizing Transcription Factor (AATF) - 0.1 mg | Anmelden | Anti-Human Apoptosis Antagonizing Transcription Factor (AATF) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Apoptosis Inducing Factor (CT) (AIF) - 0.1 mg | Anmelden | Anti-Human Apoptosis Inducing Factor (CT) (AIF) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Apoptosis Inducing Factor (NT) (AIF) - 0.1 mg | Anmelden | Anti-Human Apoptosis Inducing Factor (NT) (AIF) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Apoptosis Protease Activating Factor-1 (NT) (Apaf-1) - 0.1 mg | Anmelden | Anti-Human Apoptosis Protease Activating Factor-1 (NT) (Apaf-1) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Apoptosis Related Protein (NT) (ARTS) - 0.1 mg | Anmelden | Anti-Human Apoptosis Related Protein (NT) (ARTS) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Apoptosis Repressor with CARD Domain (CT) (ARC) - 0.1 mg | Anmelden | Anti-Human Apoptosis Repressor with CARD Domain (CT) (ARC) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Apoptosis Repressor with CARD Domain (NT) (ARC) - 0.1 mg | Anmelden | Anti-Human Apoptosis Repressor with CARD Domain (NT) (ARC) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human APRIL - 25 µg | Anmelden | Anti-Human APRIL - 25 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human APRIL - 100 µg | Anmelden | Anti-Human APRIL - 100 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human APRIL (Extracellular Domain-1) - 0.1 mg | Anmelden | Anti-Human APRIL (Extracellular Domain-1) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human APRIL (Extracellular Domain-2) - 0.1 mg | Anmelden | Anti-Human APRIL (Extracellular Domain-2) - 0.1 mg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human APRIL-Biotin - 50 µg | Anmelden | Anti-Human APRIL-Biotin - 50 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Artemin - 25 µg | Anmelden | Anti-Human Artemin - 25 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Artemin - 100 µg | Anmelden | Anti-Human Artemin - 100 µg | ||||||||||||||||
|
||||||||||||||||||
| Anti-Human Artemin-Biotin - 50 µg | Anmelden | Anti-Human Artemin-Biotin - 50 µg | ||||||||||||||||
|
||||||||||||||||||
Eigenschaften
- Einfache Durchführung - Schnelles und einfaches Verfahren
- Hohe Sensitivität - Die Empfindlichkeit der ONE-HOUR Western ™ Kits sind vergleichbar oder besser als die der klassischen 4,5-Stunden-Verfahren, je nach Qualität und Menge der verwendeten Antikörper.
- Reproduzierbare Ergebnisse
- Weniger Optimierung nötig als bei der klassische Methode
- Sekundärer Antikörper ist enthalten
- Keine besondere Markierung des Primärantikörpers erforderlich


